NO20100442L - Copolymer 1 relaterte polypeptider for anvendelse som molekylvekt markorer og for terapeutisk anvendelse - Google Patents
Copolymer 1 relaterte polypeptider for anvendelse som molekylvekt markorer og for terapeutisk anvendelseInfo
- Publication number
- NO20100442L NO20100442L NO20100442A NO20100442A NO20100442L NO 20100442 L NO20100442 L NO 20100442L NO 20100442 A NO20100442 A NO 20100442A NO 20100442 A NO20100442 A NO 20100442A NO 20100442 L NO20100442 L NO 20100442L
- Authority
- NO
- Norway
- Prior art keywords
- molecular weight
- weight markers
- copolymer
- glatiramer acetate
- related polypeptides
- Prior art date
Links
- 229920001577 copolymer Polymers 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108010072051 Glatiramer Acetate Proteins 0.000 abstract 3
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 abstract 3
- 229960003776 glatiramer acetate Drugs 0.000 abstract 3
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
Abstract
Den foreliggende oppfinnelsen tilveiebringer molekylvektsmarkører for nøyaktig bestemmelse av molekylvekten til glatirameracetat og andre copolymerer. Den foreliggende oppfinnelse tilveiebringer ytterligere en pluralitet av molekylærvektsmarkører for å bestemme molekylærvekten til glatirameracetat og andre copolymerer som utviser lineært forhold mellom molar elliptisitet og molekylærvekt og mellom retensjonstid og log av den molekylære vekten. Molekylærvektsmarkørene viser også biologisk aktivitet lik glatirameracetat eller korresponderende copolymerer og kan bli brukt for å behandle eller forebygge forskjellige immunsykdommer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10169398P | 1998-09-25 | 1998-09-25 | |
| PCT/US1999/022402 WO2000018794A1 (en) | 1998-09-25 | 1999-09-24 | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20100442L true NO20100442L (no) | 2001-05-25 |
| NO336685B1 NO336685B1 (no) | 2015-10-19 |
Family
ID=22285926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011441A NO329877B1 (no) | 1998-09-25 | 2001-03-21 | Anvendelse av molekylvektmarkorer for bestemmelse av gjennomsnittlig molekylvekt av en blanding av polypeptider samt fremgangsmate for fremstilling av et farmasoytisk produkt. |
| NO20100442A NO336685B1 (no) | 1998-09-25 | 2010-03-25 | Renset polypeptid, fremgangsmåte for å bestemme gjennomsnittlig molekylvekt til glatiramer-acetat og fremgangsmåte for å fremstille et farmasøytisk produkt som omfatter glatiramer-acetat ved bruk av slike, samt fremgangsmåte for å sertifisere glatiramer-acetat for bruk i et farmasøytisk produkt som omfatter glatiramer-acetat som har en gjennomsnittlig molekylvekt på mellom 4000 Da og 13000 Da. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011441A NO329877B1 (no) | 1998-09-25 | 2001-03-21 | Anvendelse av molekylvektmarkorer for bestemmelse av gjennomsnittlig molekylvekt av en blanding av polypeptider samt fremgangsmate for fremstilling av et farmasoytisk produkt. |
Country Status (18)
| Country | Link |
|---|---|
| EP (3) | EP1115743B1 (no) |
| JP (2) | JP4629229B2 (no) |
| AT (2) | ATE516297T1 (no) |
| AU (1) | AU757413B2 (no) |
| CA (2) | CA2794705C (no) |
| CY (3) | CY1110490T1 (no) |
| DE (2) | DE09004306T1 (no) |
| DK (3) | DK2090583T3 (no) |
| ES (3) | ES2369642T3 (no) |
| HK (3) | HK1040521A1 (no) |
| HU (3) | HU229289B1 (no) |
| IL (4) | IL142116A0 (no) |
| NO (2) | NO329877B1 (no) |
| NZ (1) | NZ511020A (no) |
| PT (3) | PT2239269E (no) |
| SI (1) | SI1115743T1 (no) |
| WO (1) | WO2000018794A1 (no) |
| ZA (1) | ZA200102269B (no) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| WO2001097785A2 (en) * | 2000-06-20 | 2001-12-27 | Caprion Pharmaceuticals Inc. | Basic copolymers for the treatment of prion-related-disease |
| US20040037828A1 (en) * | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
| DE02800437T1 (de) * | 2001-10-03 | 2004-11-11 | The President And Fellows Of Harvard College, Cambridge | Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren |
| KR100657048B1 (ko) | 2001-12-04 | 2006-12-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트의 효능 측정 방법 |
| AU2004206120B2 (en) | 2003-01-21 | 2009-09-24 | Yeda Research And Development Co. Ltd. | COP 1 for treatment of inflammatory bowel diseases |
| WO2005013885A2 (en) | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| KR20060125916A (ko) * | 2004-03-01 | 2006-12-06 | 펩팀문, 인코포레이티드 | 자가면역 질병을 치료하기 위한 방법 및 조성물 |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| HUE028833T2 (en) | 2004-09-09 | 2017-01-30 | Yeda Res & Dev | Polypeptide mixtures, compositions containing them, process for their preparation, and applications |
| US7858337B2 (en) | 2007-03-08 | 2010-12-28 | Novartis Ag | Process for the manufacture of a composite material |
| DE202010018377U1 (de) | 2009-08-20 | 2016-02-25 | Yeda Research And Development Co., Ltd. | Niedrigfrequente therapie mit glatirameracetat |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| US8709433B2 (en) | 2010-10-11 | 2014-04-29 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate |
| US9029507B2 (en) | 2011-02-14 | 2015-05-12 | Usv Limited | Copolymer-1, process for preparation and analytical methods thereof |
| JP2014530819A (ja) | 2011-10-10 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形 |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| CN104098655B (zh) * | 2013-04-09 | 2018-01-30 | 深圳翰宇药业股份有限公司 | 用于合成醋酸格拉替雷的质谱内标的多肽 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CN105218646B (zh) * | 2014-06-24 | 2018-09-21 | 深圳翰宇药业股份有限公司 | 一种用于检测醋酸格拉替雷样本的uplc方法 |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| EP3613756B1 (en) * | 2015-04-28 | 2024-02-21 | Hybio Pharmaceutical Co., Ltd. | High performance liquid chromatography method for polypeptide mixtures |
| ES2744179T3 (es) | 2015-09-24 | 2020-02-24 | Chemi Spa | Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| WO2018178973A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2009996A1 (en) * | 1989-02-17 | 1990-08-17 | Kathleen S. Cook | Process for making genes encoding random polymers of amino acids |
| US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
-
1999
- 1999-09-24 ES ES09004306T patent/ES2369642T3/es not_active Expired - Lifetime
- 1999-09-24 CA CA2794705A patent/CA2794705C/en not_active Expired - Lifetime
- 1999-09-24 IL IL14211699A patent/IL142116A0/xx unknown
- 1999-09-24 SI SI9931035T patent/SI1115743T1/sl unknown
- 1999-09-24 JP JP2000572252A patent/JP4629229B2/ja not_active Expired - Lifetime
- 1999-09-24 HU HU0103889A patent/HU229289B1/hu unknown
- 1999-09-24 CA CA2343929A patent/CA2343929C/en not_active Expired - Lifetime
- 1999-09-24 AT AT09004306T patent/ATE516297T1/de active
- 1999-09-24 DK DK09004306.8T patent/DK2090583T3/da active
- 1999-09-24 ES ES10171553T patent/ES2408706T3/es not_active Expired - Lifetime
- 1999-09-24 EP EP99949923A patent/EP1115743B1/en not_active Expired - Lifetime
- 1999-09-24 PT PT101715530T patent/PT2239269E/pt unknown
- 1999-09-24 DK DK99949923T patent/DK1115743T3/da active
- 1999-09-24 WO PCT/US1999/022402 patent/WO2000018794A1/en active IP Right Grant
- 1999-09-24 HU HU1300337A patent/HU229720B1/hu unknown
- 1999-09-24 AU AU62695/99A patent/AU757413B2/en not_active Expired
- 1999-09-24 DK DK10171553.0T patent/DK2239269T3/da active
- 1999-09-24 EP EP09004306A patent/EP2090583B1/en not_active Expired - Lifetime
- 1999-09-24 EP EP10171553A patent/EP2239269B1/en not_active Expired - Lifetime
- 1999-09-24 ES ES99949923T patent/ES2327301T3/es not_active Expired - Lifetime
- 1999-09-24 HU HU1300505A patent/HU229719B1/hu unknown
- 1999-09-24 NZ NZ511020A patent/NZ511020A/xx not_active IP Right Cessation
- 1999-09-24 PT PT99949923T patent/PT1115743E/pt unknown
- 1999-09-24 DE DE09004306T patent/DE09004306T1/de active Pending
- 1999-09-24 PT PT09004306T patent/PT2090583E/pt unknown
- 1999-09-24 DE DE69940888T patent/DE69940888D1/de not_active Expired - Lifetime
- 1999-09-24 ZA ZA200102269A patent/ZA200102269B/en unknown
- 1999-09-24 AT AT99949923T patent/ATE431359T1/de active
-
2001
- 2001-03-20 IL IL142116A patent/IL142116A/en not_active IP Right Cessation
- 2001-03-21 NO NO20011441A patent/NO329877B1/no not_active IP Right Cessation
-
2002
- 2002-01-18 HK HK02100390.4A patent/HK1040521A1/xx not_active IP Right Cessation
-
2009
- 2009-08-06 CY CY20091100835T patent/CY1110490T1/el unknown
- 2009-12-09 HK HK09111514.5A patent/HK1133021A1/xx not_active IP Right Cessation
-
2010
- 2010-03-25 NO NO20100442A patent/NO336685B1/no not_active IP Right Cessation
- 2010-06-23 JP JP2010142689A patent/JP4903886B2/ja not_active Expired - Lifetime
- 2010-11-07 IL IL209190A patent/IL209190A/en not_active IP Right Cessation
- 2010-11-07 IL IL209189A patent/IL209189A/en not_active IP Right Cessation
-
2011
- 2011-04-08 HK HK11103596.9A patent/HK1149279A1/xx not_active IP Right Cessation
- 2011-10-05 CY CY20111100947T patent/CY1112197T1/el unknown
-
2013
- 2013-04-15 CY CY20131100310T patent/CY1113932T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20100442L (no) | Copolymer 1 relaterte polypeptider for anvendelse som molekylvekt markorer og for terapeutisk anvendelse | |
| TR200001312T2 (tr) | Benzotiyazol protein tirozin kinaz önleyicileri. | |
| DK466185A (da) | Substituerede 3-aminopropanphosponsyrlingforbindelser samt deres fremstilling og anvendelse | |
| TR200102969T2 (tr) | Siklik protein tirozin kinaz önleyicileri. | |
| SE9800836D0 (sv) | New Compounds | |
| ATE239709T1 (de) | Racemisches huperzin a | |
| FI893681A0 (fi) | N-2,3-butadienyltri- och tetra-aminoalkanderivat. | |
| DE58902899D1 (de) | 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer. | |
| NO893948D0 (no) | Bornitrogenpolymerer, fremgangsmaate for deres fremstilling og anvendelse som forloepere. | |
| FI901895L (fi) | Olefiinien polymerointiin tarkoitettu prokatalyyttikompositio, sen valmistus ja käyttö | |
| DE69628659D1 (de) | Verfahren zur bestimmung von blutgerinnungsfaktoren viii und ix | |
| MX9205978A (es) | Nuevas proteinas inhibidoras de trombina de garrapatas. | |
| DK0711163T3 (da) | Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF | |
| IT1294932B1 (it) | Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie | |
| DK0625351T3 (da) | Anvendelse af etofibrat og farmaceutiske præparater indeholdende etofibrat til behandling af diabetisk angio- og retinopati | |
| FI902131A0 (fi) | Kristallina mono- och kopolymerer av propylen i form av sfaeriska partiklar med hoeg porositet. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |